Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series
Purpose of the reportAdults with Down Syndrome (DS) have a substantially increased risk for Alzheimer’s disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2024.1505999/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557868725141504 |
|---|---|
| author | Olivia Wagemann Olivia Wagemann Matthias Brendel Nicolai Franzmeier Nicolai Franzmeier Nicolai Franzmeier Georg Nübling Georg Nübling Johannes Gnörich Mirlind Zaganjori Catharina Prix Anna Stockbauer Anna Stockbauer Elisabeth Wlasich Sandra V. Loosli Sandra V. Loosli Katja Sandkühler Lukas Frontzkowski Günter Höglinger Günter Höglinger Günter Höglinger Johannes Levin Johannes Levin Johannes Levin |
| author_facet | Olivia Wagemann Olivia Wagemann Matthias Brendel Nicolai Franzmeier Nicolai Franzmeier Nicolai Franzmeier Georg Nübling Georg Nübling Johannes Gnörich Mirlind Zaganjori Catharina Prix Anna Stockbauer Anna Stockbauer Elisabeth Wlasich Sandra V. Loosli Sandra V. Loosli Katja Sandkühler Lukas Frontzkowski Günter Höglinger Günter Höglinger Günter Höglinger Johannes Levin Johannes Levin Johannes Levin |
| author_sort | Olivia Wagemann |
| collection | DOAJ |
| description | Purpose of the reportAdults with Down Syndrome (DS) have a substantially increased risk for Alzheimer’s disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Materials and methodsFive adults with DS (40% female, aged 43–62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia.ResultsVisual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages.ConclusionTau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD. |
| format | Article |
| id | doaj-art-ba2cfbe66a584ca7becb7f7afba05f4e |
| institution | Kabale University |
| issn | 1662-453X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj-art-ba2cfbe66a584ca7becb7f7afba05f4e2025-01-06T09:27:31ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-01-011810.3389/fnins.2024.15059991505999Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case seriesOlivia Wagemann0Olivia Wagemann1Matthias Brendel2Nicolai Franzmeier3Nicolai Franzmeier4Nicolai Franzmeier5Georg Nübling6Georg Nübling7Johannes Gnörich8Mirlind Zaganjori9Catharina Prix10Anna Stockbauer11Anna Stockbauer12Elisabeth Wlasich13Sandra V. Loosli14Sandra V. Loosli15Katja Sandkühler16Lukas Frontzkowski17Günter Höglinger18Günter Höglinger19Günter Höglinger20Johannes Levin21Johannes Levin22Johannes Levin23Department of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyGerman Center for Neurodegenerative Disease (DZNE), Munich, GermanyDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, GermanyDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal and Gothenburg, SwedenMunich Cluster for Systems Neurology (SyNergy), Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyGerman Center for Neurodegenerative Disease (DZNE), Munich, GermanyDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyGerman Center for Neurodegenerative Disease (DZNE), Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyDepartment of Neurology, University Hospital Zurich, Zurich, SwitzerlandDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyGerman Center for Neurodegenerative Disease (DZNE), Munich, GermanyMunich Cluster for Systems Neurology (SyNergy), Munich, GermanyDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, GermanyGerman Center for Neurodegenerative Disease (DZNE), Munich, GermanyMunich Cluster for Systems Neurology (SyNergy), Munich, GermanyPurpose of the reportAdults with Down Syndrome (DS) have a substantially increased risk for Alzheimer’s disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Materials and methodsFive adults with DS (40% female, aged 43–62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia.ResultsVisual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages.ConclusionTau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD.https://www.frontiersin.org/articles/10.3389/fnins.2024.1505999/fulldown syndromeAlzheimertau PET18F-PI-2620case seriestrisomy 21 |
| spellingShingle | Olivia Wagemann Olivia Wagemann Matthias Brendel Nicolai Franzmeier Nicolai Franzmeier Nicolai Franzmeier Georg Nübling Georg Nübling Johannes Gnörich Mirlind Zaganjori Catharina Prix Anna Stockbauer Anna Stockbauer Elisabeth Wlasich Sandra V. Loosli Sandra V. Loosli Katja Sandkühler Lukas Frontzkowski Günter Höglinger Günter Höglinger Günter Höglinger Johannes Levin Johannes Levin Johannes Levin Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series Frontiers in Neuroscience down syndrome Alzheimer tau PET 18F-PI-2620 case series trisomy 21 |
| title | Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series |
| title_full | Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series |
| title_fullStr | Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series |
| title_full_unstemmed | Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series |
| title_short | Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer’s disease: a case series |
| title_sort | feasibility and potential diagnostic value of 18f pi 2620 pet in patients with down syndrome and alzheimer s disease a case series |
| topic | down syndrome Alzheimer tau PET 18F-PI-2620 case series trisomy 21 |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2024.1505999/full |
| work_keys_str_mv | AT oliviawagemann feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT oliviawagemann feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT matthiasbrendel feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT nicolaifranzmeier feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT nicolaifranzmeier feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT nicolaifranzmeier feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT georgnubling feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT georgnubling feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT johannesgnorich feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT mirlindzaganjori feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT catharinaprix feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT annastockbauer feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT annastockbauer feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT elisabethwlasich feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT sandravloosli feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT sandravloosli feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT katjasandkuhler feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT lukasfrontzkowski feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT gunterhoglinger feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT gunterhoglinger feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT gunterhoglinger feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT johanneslevin feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT johanneslevin feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries AT johanneslevin feasibilityandpotentialdiagnosticvalueof18fpi2620petinpatientswithdownsyndromeandalzheimersdiseaseacaseseries |